Regulation Of Hematopoietic Stem Cell Development Shown By MDC Scientists

During cell division, whether (HSCs) will develop into new stem cells (self-renewal) or differentiate into other depends on a chemical process called . These were the findings of researchers at the laboratory of Dr. Frank of the for (MDC) Berlin-Buch in cooperation with the laboratory of W. Jacobsen (Lund University, Sweden and the , England). Furthermore, the researchers showed that also plays a crucial role for cancer stem cells (, online, doi: doi:10.1038/ng.463)*.

A group of three enzymes, the (Dnmt) regulates the addition of to the DNA (). One of these enzymes – Dnmt1 – is responsible for the maintenance of the marks with the , the pattern, because the distribution of the on the DNA decides which genes are transcribed and which are blocked. Researchers speak in this context of epigenetic information, in contrast to .

However, it was unclear until now whether plays a special role in the control of hematopoietic stem . From the HSCs all of the of the body are formed. Since have only a limited lifetime, the body must form new over and over again. The pool for this is generated by the HSCs.

In order to discover what function has for HSCs, the two Ann-Marie Bröske and Lena Vockentanz of the laboratory of Dr. switched off the enzyme Dnmt1 in the mice. As a result, the animals were not viable because the hematopoietic stem cell function was completely disturbed.

By contrast, when the two researchers arranged that the HSCs formed just a little Dnmt1, the animals survived, but the HSCs lost their potential for self-renewal. Moreover, the HSCs were restricted in their formation of B cells and T cells ( of the lymphatic system and important cells of the immune system).

However, the HSCs were able to form red , which are important for oxygen transport and belong to the of the myeloerythroid system. In other words, the level regulates which blood cell lineages develop or not from a hematopoietic stem cell.

Cancer stem cells

Methylation processes also play a role in numerous cancer diseases. As the MDC researchers were able to show, the by the enzyme Dnmt1 also controls the development of leukemic stem cells.

If the level is low, cancer stem cell renewal is restricted. Moreover, the formation of leukemic cells of B-cell lineage (acute B-cell leukemia – ALL) is blocked.

The question is whether diseased stem cells can be switched off, possibly through a blockade of the enzyme Dnmt1. Dr. and his research team want to make a more detailed investigation of this question in a further project.

* protects hematopoietic stem cell multipotency from myeloerythroid restriction
Ann-Marie Bröske1*, Lena Vockentanz1*, Shabnam Kharazi2, Matthew R. Huska1, Elena Mancini3, Marina Scheller1, Christiane Kuhl1, Andreas Enns1, Marco Prinz4, Rudolf Jaenisch5, Claus Nerlov3, Achim Leutz1, Miguel A. Andrade-Navarro1, Sten W. Jacobsen2,6 and Frank Rosenbauer1
1 for , 13125 Berlin, Germany
2 Hematopoietic Stem Cell Laboratory, Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund University, Lund, Sweden
3 European Molecular Biology Laboratory, Mouse Biology Unit, Monterotondo, Italy
4 Department of Neuropathology, University of Freiburg, Freiburg, Germany
5 The Whitehead Institute, 9 Cambridge Center, Cambridge, MA, USA
6 Haematopoietic Stem Cell Laboratory, Weatherall Institute of , John Radcliffe Hospital, , Oxford, England.
*These authors contributed equally to this work.

Source:
Barbara Bachtler
Helmholtz Association of German Research Centres

  • Share/Bookmark